Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Symptomatic Gastroesophageal Reflux Disease (sGERD)

In brief

The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).

Key facts

Study ID
NCT00911534
Run by
Eisai Inc.
People needed
305
Starts
2009-01-01
Expected to finish
2009-10-01
Last updated by the study team
2016-02-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.